SR9009 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-02-10. Anything still debated is marked as such rather than presented as settled.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
In this model the racemic state is unstable in the sense that the slightest enantiomeric excess will be amplified to a completely homochiral state. This can be shown by computing the reaction rates from the law of mass action:
Serena Michelle Best , is a British academic, and the Professor of Materials Science at the University of Cambridge. Best has a BSc from the University of Surrey, and a PhD from the University of London. She was elected Fellow of the Royal Academy of Engineering (FREng) in 2012. In the 2017 Birthday Honours, Best was made a CBE, "For services to Biomaterials Engineering." Best was President of the Institute of Materials, Minerals and Mining from 2019 to 2020.
Ji and Ji (1996) identified many features that set Sinosauropteryx apart from other birds and non-avian dinosaurs. They found that it was a small primitive bird with a relatively high skull, blunt rostrum and a slightly high premaxilla; that the antorbital fenestra was elliptical but not enlarged, the dentary was robust, the surangular was narrow and elongated, and the dentition is extremely well developed and acute; that there are over 50 extremely elongated caudals, constituting 60% of the body length, and the forelimb is extremely short with a short and thick humerus; the pubis was elongated and extremely inflated at its distal end and the ischium is broad; the hind limb was long and robust, the tibia is only slightly longer than the femur, the tarsals are separated, and the metatarsals are relatively robust with unfused proximal ends; the feathers are short, small, and uniform; many ornament the top of the skull, cervical, and dorsal regions, in addition to the dorsal and ventral caudal region.
== External links == Information Digest, 2022–2023 (NUREG-1350, Volume 34), NRC Reactors Designed by Argonne National Laboratory: Fast Reactor Technology Argonne pioneered the development of fast reactors and is a leader in the development of fast reactors worldwide. See also Argonne's Nuclear Science and Technology Legacy. The Changing Need for a Breeder Reactor by Richard Wilson at The Uranium Institute 24th Annual Symposium, September 1999 Experimental Breeder Reactor-II (EBR-II): An Integrated Experimental Fast Reactor Nuclear Power Station International Thorium Energy Organisation – www.IThEO.org A Path Forward for the LMFBR Plutonium Fuel Fabrication by Argonne National Laboratory on YouTube
Sources: en.wikipedia.org
Chen, Li & Shi (2026) study the cranial morphology and phylogenetic affinities of Tossunnoria pseudibex, recover the species as a member of the bovid tribe Urmiatheriini, and interpret its caprin-like morphology as a result of convergent evolution. Revision of the type material of Pachygazella grangeri is published by Bai, Wang & Dong (2026). Evidence from the study of tooth wear of extant and Pleistocene springboks, indicative of variability of dietary signals in members of the same species both within and across different biomes, is presented by Walls et al. (2026). Dumitru et al. (2026) determine that deposition of fossils of Myotragus antiquus in Cova des Fum (Mallorca, Spain) happened between 3.60 and 3.45 million years ago, indicating that M. antiquus lived years earlier than indicated by previous estimates. Armaroli et al. (2026) provide new information on the late Pleistocene Alpine ibex population from Riparo Dalmeri (Italy) on the basis of the study of strontium, carbon and oxygen isotopic composition of their remains, ancient DNA data and radiocarbon dating, reporting evidence of stable density of the studied population despite intensive hunting and consistent human presence, as well as evidence dietary differences between sexes in the studied population. Sorbelli et al. (2026) describe fossil material of "Alephis" tigneresi from the Pliocene strata from Camp dels Ninots (Spain), and assign this species to the genus Parabos. Liang et al.
Control of petroleum production has been a significant driver of international relations during much of the 20th and 21st centuries. Organizations like OPEC have played an outsized role in international politics. Some historians and commentators have called this the "Age of Oil" With the rise of renewable energy and addressing climate change some commentators expect a realignment of international power away from petrostates.
== See also == Discrete Fourier transform – Function in discrete mathematics − for computing periodicity in evenly spaced data Fourier transform – Mathematical transform that expresses a function of time as a function of frequency Fourier transform spectroscopy – Spectroscopy based on time- or space-domain dataPages displaying short descriptions of redirect targets Least-squares spectral analysis – Periodicity computation method − for computing periodicity in unevenly spaced data
Aside from the 22 proteinogenic amino acids, many non-proteinogenic amino acids are known. These either are not found in proteins (for example carnitine, GABA, ornithine) or are not produced directly and in isolation by standard cellular machinery. For example, hydroxyproline is synthesized from proline, and selenomethionine is produced by metabolic modification of methionine. Non-proteinogenic amino acids that are found in proteins are formed by post-translational modification. Such modifications can also determine the localization of the protein, e.g., the addition of long hydrophobic groups can cause a protein to bind to a phospholipid membrane. Examples:
== Radiation == The weak beta emission is stopped by the walls of laboratory glassware. Soft X-rays are emitted when the beta particles are stopped, but as long as the body is kept more than 30 cm away these should pose no problem. The primary hazard when working with technetium is inhalation of dust; such radioactive contamination in the lungs can pose a significant cancer risk.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.